Exelixis

Exelixis, Inc. is a biopharmaceutical company focused on oncology, founded in 1994 and headquartered in Alameda, California. The company is dedicated to discovering, developing, and commercializing innovative cancer therapies. Its flagship product, CABOMETYX (cabozantinib), is a small-molecule inhibitor that has gained approval for multiple cancer indications, including renal cell carcinoma and hepatocellular carcinoma. Exelixis also offers COMETRIQ (cabozantinib) for metastatic medullary thyroid cancer and COTELLIC (cobimetinib), developed in partnership for commercialization. The company has evolved from its origins in functional genomics to a multi-platform oncology firm, utilizing small molecules, biotherapeutics, and antibody-drug conjugates to tackle challenging cancers. Exelixis emphasizes patient-centric innovation and reinvests revenues from CABOMETYX into expanding its pipeline of targeted cancer therapies. The company collaborates with leading pharmaceutical partners to enhance research and market reach, ensuring its therapies are accessible to patients worldwide.